Immunic Inc. reported its financial results for the third quarter of 2025, with research and development (R&D) expenses totaling $20.0 million, down from $21.4 million in the same period in 2024. The $1.4 million decrease was mainly due to a $1.3 million reduction in external development costs related to IMU-856, a $1.1 million decrease following completion of the phase 2 CALLIPER trial in the prior year, and a $0.2 million decrease in various other costs. These decreases were partially offset by a $1.2 million increase in R&D personnel expenses, including $0.8 million related to non-cash share-based compensation. Other income (expense) was negligible in the third quarter of 2025, compared to $0.6 million in the same period in 2024, primarily due to a reduction in research and development tax incentives linked to lower clinical trial spending in Australia. The company also provided updates on its clinical programs. Data from the phase 2 CALLIPER trial showed statistically significant 24-week confirmed disability improvement in progressive multiple sclerosis, with signals suggesting slowed disability progression. Long-term phase 2 EMPhASIS data in relapsing-remitting multiple sclerosis indicated high rates of patients remaining free of confirmed disability worsening and favorable safety and tolerability. Top-line data from the twin phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis are expected by year-end 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY23042) on November 13, 2025, and is solely responsible for the information contained therein.
Comments